February 2014 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the February 2014 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings

- Baclofen (Lioresal Intrathecal) inj 0.05 mg per ml, 1 ml ampoule (p'code 2162334) and inj 2 mg per ml, 5 ml ampoule (p'code 2087081) – subsidy by endorsement
- Dexamethasone phosphate (Dexamethasone-hameln) inj 4 mg per ml, 1 ml ampoule (p'code 2451689) and inj 4 mg per ml, 2 ml ampoule (p'code 2451697)
- Dimethicone (healthE Dimethicone 5%) crm 5% pump bottle, 500 ml OP (p'code 2373319)
- Fluoxetine hydrochloride (Arrow-Fluoxetine) tab dispersible 20 mg, scored (p'code 2450879) and cap 20 mg (p'code 2450860)
- Isosorbide mononitrate (Ismo 40 Retard) tab long-acting 40 mg (p'code 2447355)
- Oral elemental feed 0.8kcal/ml (Elemental 028 Extra) liquid (grapefruit), 250 ml carton, (p'code 2450771) liquid (pineapple & orange), 250 ml carton (p'code 2450801) and liquid (summer fruits), 250 ml carton (p'code 2450798) – Special Authority
- Pharmacy Services (BSF Cellcept) brand switch fee (p'code 2452189)

Changes to restrictions, chemical names and presentations

- Atomoxetine (Strattera) cap 10, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg – amendment to Special Authority
- Dexamethasone phosphate (Hospira and Dexamethasone-hameln) inj 4 mg per ml, 1 ml ampoule and inj 4 mg per ml, 2 ml ampoule - amendment to chemical name and presentation description
- Ferrous sulphate (Ferodan) oral liq 30 mg (6 mg elemental) per 1 ml – amendment to presentation description
- Magnesium hydroxide (PSM) paste 29% - amendment to presentation description
- Magnesium hydroxide 8% mixture – amendment to Standard Formulae
- Mycophenolate mofetil (Cellcept) tab 500 mg and cap 250 mg - removal of note and addition of Brand switch fee
- Oxycodone hydrochloride (Oxydone BNM) tab controlled-release 10 mg, 20 mg, 40 mg and 80 mg – removal of Brand switch fee

Increased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
<th>Partially subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous sulphate</td>
<td>Tab long-acting 325 mg (105 mg elemental)</td>
<td>Ferrograd (30 tab packsize)</td>
<td>Ferrograd* (150 tab packsize)</td>
</tr>
</tbody>
</table>

Decreased subsidy

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Presentation</th>
<th>Fully subsidised brands</th>
<th>Partially subsidised brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound electrolytes</td>
<td>Powder for oral soln</td>
<td>Enerlyte* Electral</td>
<td></td>
</tr>
<tr>
<td>Ferrous sulphate</td>
<td>Oral liq 30 mg (6 mg elemental) per 1 ml</td>
<td>Ferodan</td>
<td></td>
</tr>
<tr>
<td>Lamivudine</td>
<td>Tab 150 mg</td>
<td>Lamivudine Alphapharm*</td>
<td>3TC</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>Inj 5 iu per ml, 1 ml ampoule and inj 10 iu per ml, 1 ml ampoule</td>
<td>Oxytocin BNM* Syntocinon</td>
<td></td>
</tr>
</tbody>
</table>
Phenoxymethylpenicillin
(penicillin V)

Grans for oral liq 125 mg per 5 ml
Grans for oral liq 250 mg per 5 ml

AFT

Urea

Crm 10 %

healthE Urea Cream*

Nutraplus

* no subsidy changes for these brands for 1 February 2014.

Apo-Ropinirole (ropinirole hydrochloride) - removal of s29 and reinstatement of certified exemption

PHARMAC has been notified that Apotex now have consent for its 0.25 mg, 1 mg, 2 mg and 5 mg Apo-Ropinirole tablets. From 1 February 2014, the s29 symbol will be removed from Apo-Ropinirole and the certified exemption symbol (▲) will be reinstated so that three months’ supply of ropinirole can be dispensed at one time if endorsed by the prescriber or pharmacist. The wastage rule will no longer apply to dispensings of Apo-Ropinirole.

These changes have not been included in the printed February 2014 Update. However, they will be included in your pharmacy software changes along with the other changes for 1 February 2014 and will be incorporated into the interactive Schedule on the PHARMAC website.